Topic: multiple sclerosis
The collaboration will analyze MRI data from 35,000 multiple sclerosis patients and results from IL-17 inhibitor trials.
A University of Chicago teams has shown that a derivative of hypertension drug Wytensin can protect myelin in animal models of multiple sclerosis.
Researchers at the University of Toronto and UCSF point to the gut as the source of immune cells that mitigate brain inflammation in MS.
Sanofi laid out $125 million to take a stake in two of Denali's RIPK1 inhibitors, and now one will be tested in three tough-to-treat brain disorders.
Capitalizing on a process the body uses to eliminate overly aggressive T cells could be a new way to treat autoimmune diseases.
Royal Philips and Ypsomed plan to install digital, at-home adherence tracking across a line of connected injection and infusion systems.
The decision comes a year after the monoclonal antibody, GNbAC1, failed to beat placebo in a phase 2b trial.
Laquinimod was once hailed as a blockbuster heir to Copaxone but suffered a string of late-phase failures that dragged down Teva.
Active Biotech and Teva delivered more bad news from their clinical development of laquinimod, this time from a phase 2 trial in Huntington’s disease.
A startup exited stealth mode to push a new class of drugs that could help regenerate nerve cells’ insulating myelin sheaths in diseases such as MS.